OCTREOTIDE
Flammability | 1 | |
Toxicity | 1 | |
Body Contact | 1 | |
Reactivity | 1 | |
Chronic | 2 | |
SCALE: Min/Nil=0 Low=1 Moderate=2 High=3 Extreme=4 |
Octapeptide (8 amino- acids) obtained from the hypothalamus or by synthesis. Naturally
occurring form is cyclical. Analogue of somatostatin with similar properties but with a
reportedly longer action. Growth hormone- release inhibiting factor. Together with growth
hormone- release factor (GRF) mediates release of growth hormone from the anterior
pituitary gland. Also has a role in regulation and secretion of pancreatic, duodenal, and
gastric secretions as well as an inhibitory effect on the secretion of several substances
including glucagon, insulin and gastrin. Has been used in the treatment of islet- cell
tumours and other neoplasms of the gastrointestinal tract associated with ectopic peptide
production, and in the treatyment of diabetes mellitus. Used in the treatment of severe,
acute haemorrhage of gastrointestinal ulcers, in erosive or haemorrhage gastritis,
experimentally as a hypoglycaemic and growth hormone inhibitor (to reduce circulating
levels in patients with agromegaly). Given by intravenous infusion.
C49-H66-N10-O10-S2, "L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-
tryptophyl-L-ysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2-7)-
disulfide, (R-(R*, R*))-", "L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-
tryptophyl-L-ysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2-7)-
disulfide, (R-(R*, R*))-", "somatotropin/ somatotrophin release inhibiting factor", "SMS
201-995", "hypothalmic hormone", "somatostatin analogue"
Although ingestion is not thought to produce harmful effects, the material may still be damaging to the health of the individual following ingestion, especially where pre- existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.
Although the material is not thought to be an irritant, direct contact with the eye may produce transient discomfort characterized by tearing or conjunctival redness (as with windburn). The dust may produce eye discomfort causing smarting, pain and redness.
The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting. Open cuts, abraded or irritated skin should not be exposed to this material.
The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.
Principal routes of exposure are by accidental skin and eye contact andinhalation of generated dusts. Exposure to small quantities may induce hypersensitivity reactions characterized by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic edema), running nose (rhinitis) and blurred vision . Anaphylactic shock and skin rash (non-thrombocytopenic purpura) may occur. An individual may be predisposed to such anti-body mediated reaction if other chemical agents have caused prior sensitization (cross-sensitivity).